Bitnile Holdings Announces Additional Investment In Alzamend From Completion Of Phase 1 First-In-Human Clinical Trial For Al001 Treatment Of Dementia Related To Alzheimer’s
Bitnile Holdings Announces Additional Investment In Alzamend From Completion Of Phase 1 First-In-Human Clinical Trial For Al001 Treatment Of Dementia Related To Alzheimer’s
04/28/22, 10:30 AM
Location
BitNile Holdings, Inc. (NYSE American: NILE), a diversified holding company (“BitNile” or the “Company”) announced today its wholly owned subsidiary, Digital Power Lending, LLC (“DP Lending”) has made an additional investment in Alzamend Neuro, Inc. (Nasdaq: ALZN) (“Alzamend”), a related party and early clinical-stage biopharmaceutical company focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders.
Company Info
Location
las vegas, south carolina, united states
Additional Info
BitNile Holdings, Inc. is a diversified holding company pursuing growth by acquiring undervalued businesses and disruptive technologies with a global impact. Through its wholly and majority-owned subsidiaries and strategic investments, the Company owns and operates a data center at which it mines Bitcoin and provides mission-critical products that support a diverse range of industries, including defense/aerospace, industrial, automotive, telecommunications, medical/biopharma, and textiles. In addition, the Company extends credit to select entrepreneurial businesses through a licensed lending subsidiary. BitNile Holdings’ headquarters are located at 11411 Southern Highlands Parkway, Suite 240, Las Vegas, NV 89141; www.BitNile.com.